Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer

Stefano Fanti 1, Karolien Goffin 2, Boris A Hadaschik 3, Ken Herrmann 4, Tobias Maurer 5, Steven MacLennan 6, Daniela E. Oprea-Lager 7, Wim JG Oyen 8,9,10, Olivier Rouvière 11,12, Nicolas Mottet 13, Anders Bjartell 14

Abstract
Purpose Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used for (re)staging prostate cancer (PCa) and as a biomarker for evaluating response to therapy, but lacks established response criteria. A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The Netherlands, to formulate criteria for PSMA PET/CT-based response in patients treated for metastatic PCa and optimal timing to use it.

Methods Panelists received thematic topics and relevant literature prior to the meeting. Statements on how to interpret response and progression on therapy in PCa with PSMA PET/CT and when to use it were developed. Panelists voted anonymously on a nine-point scale, ranging from strongly disagree (1) to strongly agree (9). Median scores described agreement and consensus.

Results PSMA PET/CT consensus statements concerned utility, best timing for performing, criteria for evaluation of response, patients who could benefit, and handling of radiolabeled PSMA PET tracers. Consensus was reached on all statements. PSMA PET/CT can be used before and after any local and systemic treatment in patients with metastatic disease to evaluate response to treatment. Ideally, PSMA PET/CT imaging criteria should categorize patients as responders, patients with stable disease, partial response, and complete response, or as non-responders. Specific clinical scenarios such as oligometastatic or polymetastatic disease deserve special consideration.

Conclusions Adoption of PSMA PET/CT should be supported by indication for appropriate use and precise criteria for interpretation. PSMA PET/CT criteria should categorize patients as responders or non-responders. Specific clinical scenarios deserve special consideration.

Keywords Monitoring, Oligometastatic prostate cancer, PERCIST, PET/CT, Polymetastatic prostate cancer, Prostate cancer, Prostate-specific membrane antigen (PSMA), PSMA ligand, RECIST
Introduction

Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is being used more frequently for prostate cancer (PCa) staging and for localization of recurrent disease [1].

International guidelines, including the guideline of the European Association for Urology (EAU) [2], have incorporated PSMA PET/CT and provide recommendation on its appropriate use. It is the consensus imaging modality in patients with rising PSA after radical treatment to confirm a diagnosis of oligorecurrent (metachronous) oligometastatic PCa [3]. In other clinical situations, such as PSA persistence after radical treatment, PSMA PET/CT is also recommended [2], while for initial staging of high-risk patients, the ultimate role of PSMA PET/CT is still debated. The most recent results of prospective trials are very promising [4, 5].

There are procedure guidelines for performing PSMA PET/CT endorsed by European Association of Nuclear Medicine (EANM) [1]. PSMA PET/CT is considered a potentially useful tool for evaluating responses to therapy, but there is lack of data regarding criteria to be used for evaluating PSMA PET/CT findings in relation to therapy response assessment [2, 4]. In recognition of the growing importance of PSMA radiopharmaceuticals in the diagnosis and treatment of patients with PCa, the EAU in collaboration with EANM recruited a panel of international experts in PCa within the fields of nuclear medicine, radiology, and urology, who met on February 21, 2020, in Amsterdam, The Netherlands, for an European consensus panel to formulate criteria for PSMA PET/CT-based response and progression in patients treated for metastatic PCa and when to use it. The main output of this meeting was the development of sets of consensus statements concerning PSMA PET/CT criteria for response assessment in various clinical scenarios for patients with metastatic PCa, and these are presented here.

Materials and methods

A modified nominal group technique was used to reach consensus statements on PSMA PET/CT response assessment criteria [6, 7]. Ten weeks prior to meeting, each panelist received thematic topics concerning PSMA PET/CT response assessment along with relevant literature suggested by the panelists. The panelists (Stefano Fanti, Karolien Goffin, Boris Hadaschik, Ken Herrmann, Tobias Maurer, Daniela Oprea-Lager, Wim JG Oyen, Olivier Rouvière, and Anders Bjartell), all authors of this paper, are PCa experts in nuclear medicine (five panelists), radiology (one panelist), or urology (three panelists). A one-day meeting was held, where the thematic topics were again presented. The panelists were subsequently divided into two groups, each containing a balance of experts in the aforementioned specialties, to separately discuss these thematic topics in greater detail and develop statements related to the use of PSMA PET/CT. The breakout groups then reconvened, discussed all statements written by each subgroup, and created a combined list of statements organized under thematic topics.

For the scope of the present project, PSMA PET/CT refers to PET/CT imaging performed with PSMA-targeting radioligands (e.g., [68Ga]Ga-PSMA-11, [18F]F-PSMA-1007, [18F]DCFPyL).

Each statement was singular and phrased so that panel members could agree or disagree with it. The resulting statements were uploaded to an online voting tool, and the panelists voted anonymously online [8]. Panelists voted on a nine-point scale, ranging from strongly disagree (1) to strongly agree (9) (i.e., 1–3 disagree, 4–6 uncertain, 7–9 agree). The results of the vote on each statement were conveyed to participants immediately after voting.

The statistical analysis of the voting focused on the level of agreement (median score) with each statement and whether there was consensus (dispersion of scores around the median). This followed the methods proposed by the research and development project (RAND)/University of California, Los Angeles (UCLA) Appropriateness Method which has been shown to be robust for smaller panels and can be used in panels of any size [9]. For each statement, first the median score was calculated, then the 30th and 70th percentiles were calculated, which constitute the interpercentile range (IPR). The IPR was used to calculate the interpercentile range adjusted for symmetry (IPRAS), which is calculated using the formula: IPRAS = 2.35 + (asymmetry index [AI] * 1.5), where the AI is defined as the absolute difference between the central point of the IPR and 5 (i.e., the central point on the 1–9 scale). If the IPR < IPRAS, then this indicates there is no extreme dispersion of scores (i.e., there is “consensus”).

The median agreement score (MAS) was used to determine the level of agreement: a MAS in the 1–3 range indicated the panel disagreed with the statement, a MAS in the 4–6 range indicated the panel were uncertain, and a MAS in the 7–9 range indicated the panel agreed with the statement. Then, the IPRAS was used to assess consensus. For a statement to be considered to have agreement and consensus, two conditions had to be met: a median score in the 7–9 category and an IPRAS < IPR.

Results

Within the scope of each thematic topic, statements were developed by the panelists during the one-day meeting concerning how to interpret PSMA PET/CT to define response and progression in patients treated for metastatic PCa and when to use it. These thematic topics and statements along
with the corresponding MAS, IPR, and IPRAS from the voting are reported in Table 1. Briefly, the statements covered the best timing for performing PSMA PET/CT, the criteria that should be used to evaluate the PSMA PET/CT response, the patients who could benefit from such evaluation from a clinical perspective, and how the various PSMA-targeting PET tracers should be handled.

Other relevant thematic topics were also addressed with statements: Available real-world data and/or trial data should be analyzed for response assessment with PSMA PET/CT before designing future prospective trials; Criteria for treatment assessment should be evaluated in test-retest trials to assess normal variability in the measurement. In every instance, the MAS fell in the 7–9 category and IPR as lower than IPRAS, so there was “agreement” and “consensus.”

As an antecedent to the discussion of the thematic topics, the panelists considered the utility and impact of PSMA PET/CT in PCa and developed four statements and reached consensus on all four.

- PSMA PET/CT is currently the most sensitive imaging staging technique for depicting metastases at any stage of the disease. MAS = 8 (IPR = 1; IPRAS = 7.6).
- Use of PSMA PET/CT will cause stage migration, which is a problem for clinical decision-making. MAS = 8 (IPR = 0; IPRAS = 6.85).
- PSMA PET/CT should be used as imaging tool at biochemical recurrence. MAS = 9 (IPR = 0; IPRAS = 8.35).
- PSMA PET/CT should not be used in low-risk disease. MAS = 9 (IPR = 0; IPRAS = 8.35).

Discussion

All consensus statements were developed following the European Society for Radiotherapy and Oncology (ESRO) and European Organisation for Research and Treatment of Cancer (EORTC) consensus recommendations for classification of oligometastatic disease [10].

General statements

Regarding the use of PSMA PET/CT for assessing response to therapy, it was confirmed that such an approach should be used only if a change of clinical management is expected from the results (statements 1.2 and 2.4) as already emphasized in EAU Guidelines [2]. Thus, in case of good PSA response after salvage treatment, there is no indication for performing PSMA PET/CT (statement 1.4); also, in case of late-stage disease where no further therapies can be initiated or hormone sensitive PCa with favorable PSA response under systemic therapy, there is no role for PSMA PET/CT (statements 1.5 and 1.6).

Asking whether PSMA PET/CT can be used before, after, and during treatment is an important question, because there are, for example, concerns regarding how to interpret uptake of tracer especially in hormone-naive patients starting androgen deprivation therapy (ADT) [11]. Consensus was reached on the statement that in principle, PSMA PET/CT can be used before and after any local and systemic treatment in patients with metastatic disease (including N1 disease). PSMA PET/CT is actually the most sensitive technique to detect metastases, and thus, it is likely that the prognosis of M0 and M+ patients based on PSMA PET/CT will be changed, as compared to the prognosis of M0 and M+ patients based on standard work up (CT and bone scan). Nonetheless, in the absence of clinical trials assessing the prognosis of patients with metastases detected only by PSMA, it remains unclear whether PSMA PET/CT should be widely used in high-risk patients.

The panel is well aware that the proposed criteria are based on practical experience and authors’ opinions; indeed, there is very little data to ultimately support some of the statements that are made. Nonetheless, it is clear that some baseline criteria are proposed to be used for future studies and applied for clinical scenarios that are already happening. With expected publication of more data from prospective studies, it will hopefully be possible to refine the statements proposed here, possibly with future further consensus events to be held for review of datasets with outcome measures. Once the criteria have been evaluated in clinical trials, they could surely be improved.

Timing for PSMA PET/CT

With respect to the best timing for performing PSMA PET/CT, some evident prerequisites were confirmed, such as that in case of primary PCa negative on PSMA PET/CT, further imaging with PSMA PET/CT is generally not adequate (statement 2.1), and if used for response assessment, baseline PSMA PET/CT should be performed before the start of treatment (statement 2.2).

The panelists agreed that potential flare observed in a PSMA scan following initiation of ADT is an early event, and misinterpretation can be avoided by performing the scan not earlier than 3 months after the start of ADT (see also statement 2.3). Data concerning the flare phenomenon observed with ADT and second-generation anti-androgen therapy are limited and not unequivocal [12–15]. The correlation between androgen signaling and PSMA expression seems to be quite complex and requires more study before practice-defining conclusions can be drawn. Nonetheless, the panelists, based on their practical experience, suggested 3 months as the minimal timing for performing PSMA PET/CT after initiation of hormonal intervention. A prospective study has shown that androgen deprivation therapy could impact the timing for PSMA PET/CT [16]. The study included 15 men, eight patients with metastatic hormone sensitive PCa treated with luteinizing hormone-releasing hormone and bicalutamide and
| Statement | MAS | IPR | IPRAS |
|-----------|-----|-----|-------|
| 1. Can PSMA PET/CT be used before and after any treatment? | | | |
| 1.1 In principal, PSMA PET/CT can be used before and after any local and systemic treatment in patients at risk of having metastatic disease (including N1 disease). | 81 | 7 6.0 | |
| 1.2 PSMA PET/CT should not be used if no change of clinical management is expected. | 90 | 8 6.35 | |
| 1.3 PSMA PET/CT should not be used if local disease within the prostate is expected. | 81 | 7 6.0 | |
| 1.4 After salvage treatment of oligometastatic PCa with curative intent, if PSA indicates complete response, PSMA PET/CT is to be avoided as an assessment tool. | 90 | 8 6.35 | |
| 1.5 Routine use of PSMA PET/CT should not be used in patients with hormone sensitive PCa and PSA response under systemic therapy. | 8 | 6 7.3 | |
| 1.6 Routine use of PSMA PET/CT should not be used in patients with late-stage disease where no further therapies can be initiated. | 7 | 0 5 35 | |
| 2. What is the best timing for performing PSMA PET/CT? | | | |
| 2.1 In cases where the primary PCa is negative on PSMA PET/CT, further staging with PSMA PET/CT is generally not adequate, and other imaging should be performed. | 90 | 8 6.35 | |
| 2.2 If used for response assessment, then a PSMA PET/CT should be performed before the start of treatment (i.e., baseline PSMA PET/CT). | 90 | 8 6.35 | |
| 2.3 PSMA PET/CT should not be performed within three months after initiation of systemic therapy in hormone sensitive PCa. | 90 | 8 6.35 | |
| 2.4 PSMA PET/CT should not be performed for routine follow-up if management of the patient is unlikely to change. | 90 | 8 6.35 | |
| 2.5 Which PET criteria should be used to evaluate the PSMA response? | | | |
| 2.1 For clinicians, PSMA PET/CT should always be accompanied by evaluation of clinical and laboratory data. | 90 | 8 6.35 | |
| 2.2 For imaging specialists, only treatment response criteria for PSMA PET/CT are needed (not taking other parameters into account (e.g. PSA, etc.). | 90 | 8 6.35 | |
| 2.3 Ideally, PSMA PET/CT criteria should categorize patients as responders or non-responders. | 90 | 8 6.35 | |
| 2.4 Categories of responders should include patients with stable disease and partial and complete response on PSMA PET/CT imaging; non-responders should include patients with progressive disease on PSMA PET/CT. | 8 | 1 6.85 | |
| 2.5 In early recurrent PCa, appearance of any new lesion with high suspicion should be regarded as progressive disease. | 8 | 1 6.85 | |
| 2.6 In polymetastatic PCa, increase of uptake or tumor volume > 30% is defined as progressive disease. | 8 | 1 6.85 | |
| 2.7 In polymetastatic PCa, appearance of two or more new lesions should not be regarded as progressive disease, if total tumor volume or uptake does not increase > 30%. | 9 | 1 6.85 | |
| 2.8 PCWG3-criteria for evaluation of bone scintigraphy should not necessarily be used for PSMA PET/CT evaluation. | 9 | 0 6.85 | |
| 2.9 Complete response: complete disappearance of any lesion with tracer uptake; partial response: reduction of uptake and tumor volume by > 30%; SD: change of uptake and tumor volume ± ≤ 30% and no new lesions; progressive disease: appearance of two or more new lesions and/or increase of uptake or tumor PET volume > 30%. | 9 | 0 6.85 | |
| 3. Which patients could benefit from PSMA response assessment from a clinical perspective (other than those for whom a treatment change will have a significant impact on outcome)? | | | |
| 3.1 PSMA PET/CT response assessment should be evaluated in the context of clinical trials. | 9 | 0 8.35 | |
| 3.2 In clinical practice, PSMA PET/CT response assessment should be performed in patients with inconsistent laboratory findings and/or clinical course of the disease if change of management is considered. | 9 | 0 8.35 | |
| 4. How should the various PET tracers be handled? | | | |
| 4.1 Different 68Ga and 18F radiolabeled PSMA tracers (e.g., [68Ga]Ga-PSMA-11, [18F]PSMA-1007, and [18F]DCFPyL) show similar performance even if there is lack of comparative data. | 8 | 1 6.85 | |
| 4.2 For response assessment the same PSMA PET tracers should be used. | 9 | 0 8.35 | |
| 4.3 Quality assurance is mandatory either for radioimaging production and image acquisition and should include EARL-harmonized protocols (scanner, reconstruction algorithms) regarding dosage, time of acquisition and quantification should be done using validated software. | 9 | 0 8.35 | |
| 6. Other relevant statements | | | |
| 6.1 Available real-world data and/or trial data should be analyzed for response assessment with PSMA PET/CT before designing future prospective trials. | 9 | 0 8.35 | |
| 6.2 Criteria for treatment assessment should be evaluated in test-rettest trials to assess normal variability in the measurement. | 9 | 1 7.6 |
seven patients with castration resistant PCa treated with enzalutamide or abiraterone, and showed that at 9 days post treatment, $[^{68}\text{Ga}]\text{Ga-PSMA-11}$ PET/CT SUVmax decreased in the hormone-sensitive patients (median 30% (interquartile range 5–61) but increased in the castration-resistant PCa (median 45% (interquartile range 12.7–66)).

Criteria for interpretation of PSMA PET/CT

Criteria to be used to evaluate PSMA response were thoroughly discussed and addressed. Indeed, molecular response criteria have been proposed as better than morphological criteria in patients with metastatic castration resistant PCa [17], but the precise criteria to be used have not been identified. There are no clear definitions for oligometastatic and polymetastatic disease, so, in the context of this report, progression was defined in order to start creating guidance on how to use PSMA PET/CT. In general, there is confidence in drawing conclusions in cases with complete response as well as for detecting clear progression of disease and scoring of new lesions [18–20], but uncertainty remains for everything in between.

The panelists agreed that PSMA PET/CT criteria should categorize patients as responders or non-responders (statement 3.3) for both, clinical use and trial incorporation. Given the nature of PCa, it was agreed that categories of responders should include patients with stable disease, partial response, and complete response on PSMA PET/CT imaging; non-responders should include patients with progressive disease on PSMA PET/CT (statement 3.3). In this light, the consensus statements were written with progression defined as a 30% increase of tumor burden, and this is in line with other studies and modified PET response criteria in solid tumors (PERCIST) [21–23]. In general, the panel agreed on a definition of PSMA response as Complete in case of disappearance of any lesion with tracer uptake; Partial as reduction of uptake and tumor PET volume > 30%; Stable as change of uptake and tumor PET volume ± 30% without evidence of new lesions; Progression as appearance of ≥2 new lesions or increase of uptake or tumor PET volume >= 30% (statement 3.9).

While these criteria are ready to be used in most situations, and should be evaluated in future studies, some specific clinical scenarios deserve special consideration. The definition of progression indicated by the panel is largely in line with the proposal of PSMA PET progression [18], largely based on the appearance of ≥2 new lesions, which is adequate in many cases. Nonetheless, the panelists agreed that in early recurrent PCa, appearance of any new lesion with high suspicion should be regarded as progressive disease (statement 3.5). The rationale was to maximize the sensitivity of the approach in such settings, where additional local therapies may still be proposed. Conversely, in polymetastatic PCa, increase of uptake or tumor PET volume > 30% was regarded as progression; appearance of two or more new lesions should not be necessarily regarded as progressive disease, if total tumor PET volume or uptake does not increase > 30% (statements 3.6 and 3.7). For the purpose of this project, the definition of a new lesion is based on the appearance of a new focal area of PSMA uptake at PET, with or without CT change. Disease progression should not be based solely on PET/CT. The rationale here was to avoid misinterpretation of progressive disease in case of an overall good response of known lesions to systemic therapy with only appearance of a few minor lesions. Indeed, it would be a mistake to switch an active treatment too early in polymetastatic situations.

Semi-quantitative evaluation of radiolabeled PSMA PET/CT scans could be very useful when assessing response to treatment. Standardized uptake value (SUV) is the most commonly used semi-quantitative parameter, providing a measure of radiotracer uptake. The main recommendation for using SUV parameters, (SUVmax, SUVmean, or SUVpeak) is to optimize reproducibility by limiting all variation factors (quality of injection, uptake time, type of scanner, reconstruction algorithm, and others), namely to rigorously harmonize procedures and parameters in all scans. Volumetric PET measurements (so called tumor burden values) based on available software packages can partly overcome such problems [24, 25], since they account for less variations across patients and are better reproducible. However, these parameters are still not widely used in clinical practice because they are technically demanding. Tools for quantitative estimation of the total tumor burden are under development, and these could reduce current problems with interobserver variability and low reproducibility with manual interpretation of images.

The use of uptake thresholds based on PERCIST could not be supported by the literature, because these have only been validated for FDG PET. Nonetheless, the panelists agreed that a threshold should be arbitrarily chosen as baseline for future studies; furthermore, it should be at least wider than repeatability coefficients (published only for the PSMA-targeted agent DCFPyL) and could be modified in the future to hopefully arrive at the appropriate cut-offs for tumor response [25].

Need for standard interpretation of scans

Quality standards for interpretation of PSMA PET/CT scans are needed. Visual, qualitative assessment of the attenuated and non-attenuated PET images is the basis of any PET study interpretation. The major concern regarding this assessment is the significant inter- and intra-observer variability of PET image interpretation. Therefore, quality standards for interpretation of PSMA PET/CT scans are needed. Yet, the report from the nuclear medicine physician needs to adhere to quality standards, as recently proposed in the E-PSMA: the EANM standardized reporting guidelines for PSMA PET/CT. The quality of the procedure itself is standardized using existing
procedures guidelines to obtain high-quality imaging [1], and the same applies to quantification software.

Different PSMA tracers, including $^{68}$Ga$-$PSMA-11 and $^{18}$F$-$labeled PSMA-1007 and $^{18}$F$-$DCFPyL tracers, are supposed to perform similarly, even if there is lack of comparative data [26]. For response assessment, it is evident that the same PSMA PET tracers should be used for baseline and subsequent imaging. Quality assurance is mandatory for both radiotracer production and image acquisition.

**Limit of the methodology**

There was consensus for every statement, and this is undoubtedly related to the fact that the panel mostly created the statements on the meeting day and discussed them in depth before voting. In-group bias is therefore a potential limitation, but the panel were sampled from the two most directly relevant professional societies (EANM and EAU) and these individuals represent expertise on this topic. Furthermore, voting was anonymous, so had any participant disagreed with the statements, there was a channel to express disagreement.

The panelists refrained from evaluating response to some particular therapies due to lack of data. As previously mentioned, the proposed criteria were mainly based on practical experience. Lutetium PSMA, due to its theranostic nature, is the only treatment where PSMA PET/CT has been used more frequently to evaluate response to therapy [27, 28]. For this indication, PSMA PET/CT is mandatory for establishing the suitability of treatment, and prognostic information can be derived from baseline PSMA PET/CT [29]. It is also possible, that PSMA PET/CT could be used to describe duration of response and decide the frequency of treatment.

**Perspective**

Available real-world data and/or trial data should be analyzed for response assessment with PSMA PET/CT before designing future prospective trials. Furthermore, criteria for treatment assessment should be evaluated in test-retest trials to assess normal variability in the measurement.

**Conclusions**

PSMA PET/CT is currently the most rapidly growing imaging technique in PCa, but its adoption should be adequately supported by indication for appropriate use and precise criteria for interpretation. PSMA PET/CT holds great potential in several clinical situations. Use of PSMA PET/CT should not be considered, if no change of clinical management is expected.

For evaluation of response to treatment, PSMA PET/CT can be used before and after any local and systemic treatment in patients with metastatic disease. However, it should not be performed within 3 months after initiation of systemic therapy in hormone sensitive PCa.

Ideally, PSMA PET/CT criteria should categorize patients as responders or non-responders: categories of responders include patients with stable disease, partial response, and complete response on PSMA PET/CT imaging. Specific clinical scenarios such as oligometastatic or polymetastatic disease deserve special consideration. The use of PSMA PET/CT response assessment should be implemented and evaluated in the context of clinical trials.

EAU and EANM endorse and promote high-quality standards in performing and reporting PSMA PET/CT scans.

**Acknowledgments**
The authors acknowledge John William Bean PhD (Bean Medical Writing, Halle, Belgium, and funded by EAU Research Foundation) for providing medical writing services and Wim Witjes MD PhD (Scientific and Clinical Research Director EAU Research Foundation) and Emily Speiker (Management Assistant, European Association of Urology) for project management.

**Author contributions**

Stefano Fanti and Anders Bjartell had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: All authors

Acquisition of data: Stefano Fanti, Karolien Goffin, Boris Hadaschik, Ken Herrmann, Tobias Maurer, Steven MacLennan, Daniela Oprea-Lager, Wim JG Oyen, Olivier Rouvière, and Anders Bjartell

Analysis and interpretation of data: All authors

Drafting of the manuscript: All authors

Critical revision of the manuscript for important intellectual content:

All authors

Statistical analysis: Steven MacLennan

Obtaining funding: Anders Bjartell

Supervision: Anders Bjartell

**Funding information**

Open Access funding provided by Lund University. The one-day EAU/EANM PSMA PET/CT Response Assessment Criteria meeting received an unrestricted grant from Janssen, and no influences on the content of the meeting or on the publication.

**Compliance with ethical standards**

**Conflict of interest**

Stefano Fanti reports personal fees from ANMI, Astellas, Bayer, BlueEarth Diagnostics, GE Healthcare, Janssen, Novartis, and Sofie Biosciences, and non-financial support from AAA, Bayer, GE Healthcare, Curium, Tema Sinergie, Sanofi, Telix, outside the submitted work; Karolien Goffin reports personal fees from Bayer, Blue Earth Diagnostics, GE Healthcare, and Lightpoint Medical, outside the submitted work; Boris Hadaschik reports personal fees from ABX, Bayer, Lightpoint Medical, Inc., Janssen R&D, Bristol-Myers-Squibb, and Astellas; research funding from Profound Medical, German Cancer Aid, German Research Foundation, Janssen R&D, Bristol-Myers-Squibb, MSD, Pfizer, and Astellas; and travel from AstraZeneca, Janssen R&D, and Astellas; Ken Herrmann reports personal fees from Bayer, other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Ams, personal fees from Novartis, and personal fees from Y-mAbs,
outside the submitted work; Tobias Maurer reports personal fees from Astellas, Bayer, BlueEarth Diagnostics, Janssen Cilag ROTOP, Phillips, and grants from Acelity, outside the submitted work; Steven MacLennan reports no conflicts of interest; Daniela Oprea-Lager has no personal fees to report, except for the unrestricted grant received from Janssen for the one-day EAU/EANM PSA PET/CT Response Assessment Criteria meeting; Wim JG Oyen has no personal fees to report, except for the unrestricted grant received from Janssen for the one-day EAU/EANM PSA PET/CT Response Assessment Criteria meeting; OR reports personal fees from Takeda and an unrestricted grant from Janssen for the one-day EAU/EANM SMA PET/CT Response Assessment Criteria meeting; NM reports personal fees as advisor with Astellas, Jansen, BMS, Bayer, IPSEN, Ferring, Sanofi, and Steba; Anders Bjartell reports personal fees from Astellas, Bayer, Ferring, IPSEN, and Janssen, and institutional research grants from Astellas and Ferring, outside the submitted work.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Mol Imaging. 2017;44:1014–24. https://doi.org/10.1007/s00259-017-3670-z.

2. Edn. presented at the EAU Annual Congress Barcelona 2019. EAU Guidelines: prostate cancer. Uroweb n.d. https://uroweb.org/guideline/prostate-cancer/ (accessed Feb 24, 2020).

3. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, et al. Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020. https://doi.org/10.1016/j.euro.2020.01.012.

4. Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RDA, et al. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int. 2018;122:783–93. https://doi.org/10.1111/bju.14374.

5. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study. Lancet 2020;0. https://doi.org/10.1016/S0140-6736(20)30314-7.

6. Delbecq A, Van de Ven A. A group process model for problem identification and program planning - André L. Delbecq, Andrew H. Van de Ven, 1971. JABS. 1971;7:466–92.

7. Harvey N, Holmes CA. Nominal group technique: an effective method for obtaining group consensus. Int J Nurs Pract. 2012;18:188–94. https://doi.org/10.1111/j.1440-172X.2012.02017.x.

8. Live interactive audience participation. Poll Everywhere n.d. https://www.polleverywhere.com (accessed Mar 5, 2020).

9. Fitch K, Bernstein SJ, Aguilar MD, Bumard B, LaCalle JR, Lazaro P, et al. The RAND/UCLA Appropriateness Method User’s Manual: 2001. https://www.rand.org/pubs/monograph_reports/ MR1269.html (accessed Feb 26, 2020).

10. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21:e18–28. https://doi.org/10.1016/S1470-2045(19)30718-1.

11. Onal C, Guler OC, Torun N, Reyhan M, Yaprak AF. The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. Eur J Nucl Mol Imaging. 2020;47:632–41. https://doi.org/10.1007/s00259-019-04581-4.

12. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg M, et al. Impact of Ga-68 PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med 2017; jnumed.117.192476. https://doi.org/10.2967/jnumed.117.192476.

13. Aggarwal R, Wei X, Kim W, Small EI, Ryan CJ, Carroll P, et al. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol. 2018;1:78–82. https://doi.org/10.1016/j.euo.2018.03.010.

14. Zukotsynski KA, Vanliant J, Bénard F, Rowe SP, Kim CK, Pomper MG, et al. Flare on serial PSMA-targeted 18F-DCFPyL PET/CT examinations in castration-resistant prostate cancer: first observations. Clin Nucl Med. 2018;43:213–6. https://doi.org/10.1097/RLU.0000000000001966.

15. Afsar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Mol Imaging. 2018;45:2045–54. https://doi.org/10.1007/s00259-018-4079-z.

16. Emmett LM, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, et al. Rapid modulation of PSMA expression by androgen deprivation: serial 68GaPSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer: Versioning androgen blockade. J Nucl Med 2018;jnumed.118.223099. https://doi.org/10.2967/jnumed.118.223099.

17. Gupta M, Choudhury P, Rawal S, Goel H, Rao S. Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: a comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography. Urol Ann. 2019;11:155. https://doi.org/10.4103/UA.UA_111_18.

18. Fanti S, Hadachisk B, Herrmann K. Proposal of systemic therapy response assessment criteria in time of PSMA PET/CT imaging: PSMA PET Progression (PPP). J Nucl Med 2019: jnumed.119.233817.https://doi.org/10.2967/jnumed.119.233817.

19. Rowe S, Pienta K, Pomper MG, Gorin M. Proposal of a structured pathway blockade in metastatic prostate cancer. J Nucl Med 2017:jnumed.118.195255.https://doi.org/10.2967/jnumed.118.195255.

20. Eiber M, Herrmann P, Calais J, Hadachisk B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59:469–78. https://doi.org/10.2967/jnumed.117.198119.
21. Grubmüller B, Senn D, Kramer G, Baltzer P, D’Andrea D, Grubmüller KH, et al. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1063–72. https://doi.org/10.1007/s00259-018-4236-4.

22. Seitz AK, Rauscher I, Haller B, Krönke M, Luther S, Heck MM, et al. Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45:602–12. https://doi.org/10.1007/s00259-017-3887-x.

23. Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017;44:55–66. https://doi.org/10.1007/s00259-017-3687-3.

24. Pollard J, Raman C, Zakharia Y, Tracy CR, Nepple KG, Ginader T, et al. Quantitative test-retest measurement of 68 Ga-PSMA-HBED-CC (PSMA-11) in tumor and normal tissue. J Nucl Med 2019: jnumed.119.236083. https://doi.org/10.2967/jnumed.119.236083.

25. Jansen BHE, Cysouw MCF, Vis AN, van Moorselaar RJA, Voortman J, Bodar YJL, et al. Repeatability of quantitative 18F-DCFPyL PET/CT measurements in metastatic prostate cancer. J Nucl Med. 2020. https://doi.org/10.2967/jnumed.119.236075.

26. Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, et al. PSMA ligands for PET imaging of prostate cancer. J Nucl Med. 2017;58:1545–52. https://doi.org/10.2967/jnumed.117.191031.

27. Ferdinandus J, Violet J, Sandhu S, Hicks RJ, Ravi Kumar AS, Iravani A, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04723-z.

28. Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, et al. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol. 2018;19:e696–708. https://doi.org/10.1016/S1470-2045(18)30604-1.

29. Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, et al. Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer. J Nucl Med 2019: jnumed.119.236414. https://doi.org/10.2967/jnumed.119.236414.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.